- Advertisement -
Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new chief executive.
Revenue will rise only as much as 11 percent this year while operating profit expands by 7 percent at most based on constant exchange rates, the Danish drugmaker said Wednesday. The trim comes as the company reported disappointing earnings for the third quarter. The stock slumped in early trading before reversing…
